Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference
Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), ”), a leader in RNA-based therapeutics, announced today the successful completion of a Phase 1 clinical trial ...
News Medical on MSN6h
ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025
ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members ...
pharmaphorum13h
MSD licenses Lp(a) heart drug from Hengrui in $2bn deal
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $45.00 by Analysts at JPMorgan Chase & Co.
Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective lowered by JPMorgan Chase & Co. from $47.00 to $45.00 in a research report released on Monday,Benzinga reports. JPMorgan Chase ...